Description
Product Overview / 商品概要
Reslin Tablets 50mg (レスリン錠50)
Generic: Trazodone Hydrochloride / トラゾドン塩酸塩
Therapeutic Category: Antidepressant / うつ病・うつ状態治療剤
Manufactured by: Organon Japan Co., Ltd. / オルガノン株式会社
Composition & Specification / 組成・規格
Active Ingredient: Trazodone Hydrochloride 50.0mg per tablet / 1錠中 トラゾドン塩酸塩 50.0mg
Additives: Lactose hydrate, Corn starch, Hydroxypropylcellulose, Magnesium stearate, Hypromellose, Low-substituted hydroxypropylcellulose, Titanium oxide / 乳糖水和物、トウモロコシデンプン、ヒドロキシプロピルセルロース、ステアリン酸マグネシウム、ヒプロメロース、低置換度ヒドロキシプロピルセルロース、酸化チタン
Appearance: Film-coated tablet, white, diameter: 7.1mm, thickness: 3.5mm, weight: 128.0mg, identification code: XD2
外観: フィルムコーティング錠・白色、直径:7.1mm、厚さ:3.5mm、重さ:128.0mg、識別コード:XD2
Indications / 効能効果
EN: Depression and depressive states
JA: うつ病・うつ状態
Dosage and Administration / 用法用量
EN: The usual initial dose for adults is 75 to 100mg per day as trazodone hydrochloride, which may be increased up to 200mg per day, administered orally in 1 to several divided doses. The dose may be adjusted according to age and symptoms.
JA: トラゾドン塩酸塩として、通常、成人には1日75~100mgを初期用量とし、1日200mgまで増量し、1~数回に分割経口投与する。なお、年齢、症状により適宜増減する。
Contraindications / 禁忌
EN: Patients with a history of hypersensitivity to any component of this product
JA: 本剤の成分に対し過敏症の既往歴のある患者
Regulatory Information / 規制情報
Approval No.: 20300AMZ00445000
Sales Started: November 1991 / 1991年11月
Classification Code: 871179
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年
Packaging / 包装
Main Package (for sale): 100 tablets [10 tablets (PTP) x 10] / 100錠[10錠(PTP)×10]
Other Available Packages (by special order): 100 tablets [10 tablets (PTP) x 10]
Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.


![Ofloxacin Otic Solution 0.3% [CEO] (Ofloxacin Otic Solution CEO® / オフロキサシン耳科用液0.3%「CEO」)](https://jp-pharma.com/wp-content/uploads/2026/06/OFL-03-OTC_1200x1200-324x324.jpg)

Reviews
There are no reviews yet.